---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-112136"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:50:16.234126+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve option repricing to $1.50; CTAD presentations set for Dec 1-4

## Summary
- Special meeting approves repricing of up to 5,511,000 outstanding stock options for employees, execs, and directors to $1.50 per share.
- Voting results: 7,144,433 for, 2,926,973 against, 121,836 abstentions.
- Repricing effective Nov 18; exercise price set at closing price of $1.50 on Nasdaq that day.
- Two presentations at CTAD conference Dec 1-4: Phase 2 MINDFuL trial results for XPro1595 in early Alzheimer’s, and EMACC validation.
- Phase 2 trial data on selective soluble TNF neutralizer XPro1595 to be presented as a poster.

## SEC filing metadata
- accession: 0001213900-25-112136
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025112136/0001213900-25-112136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025112136/ea0266048-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-112136
- JSON: https://secwatch.observer/filing/0001213900-25-112136.json
- Plain text: https://secwatch.observer/filing/0001213900-25-112136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.